AddLife AB (publ) (ALIF-B.ST)
SEK 137.2
(2.39%)
SEK 137.2
(2.39%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 190 Million SEK | -60.42% |
| 2022 | 480 Million SEK | -33.24% |
| 2021 | 719 Million SEK | 38.86% |
| 2020 | 517.8 Million SEK | 268.28% |
| 2019 | 140.6 Million SEK | 8.74% |
| 2018 | 129.3 Million SEK | 7.48% |
| 2017 | 120.3 Million SEK | 7.6% |
| 2016 | 111.8 Million SEK | 43.7% |
| 2015 | 77.8 Million SEK | -23.73% |
| 2014 | 102 Million SEK | 30.77% |
| 2013 | 78 Million SEK | 5.69% |
| 2012 | 73.8 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 72 Million SEK | 16.13% |
| 2024 Q3 | 24 Million SEK | -66.67% |
| 2024 Q1 | 62 Million SEK | 251.22% |
| 2023 Q1 | 174 Million SEK | 185.25% |
| 2023 Q3 | 25 Million SEK | -21.88% |
| 2023 Q2 | 32 Million SEK | -81.61% |
| 2023 FY | 190 Million SEK | -60.42% |
| 2023 Q4 | -41 Million SEK | -264.0% |
| 2022 Q4 | 61 Million SEK | -49.17% |
| 2022 Q2 | 74 Million SEK | -67.11% |
| 2022 Q1 | 225 Million SEK | 26.69% |
| 2022 FY | 480 Million SEK | -33.24% |
| 2022 Q3 | 120 Million SEK | 62.16% |
| 2021 Q4 | 177.6 Million SEK | 28.7% |
| 2021 FY | 719 Million SEK | 38.86% |
| 2021 Q1 | 226 Million SEK | 3.76% |
| 2021 Q2 | 177 Million SEK | -21.68% |
| 2021 Q3 | 138 Million SEK | -22.03% |
| 2020 FY | 517.8 Million SEK | 268.28% |
| 2020 Q4 | 217.8 Million SEK | 72.86% |
| 2020 Q3 | 126 Million SEK | 5.88% |
| 2020 Q2 | 119 Million SEK | 120.37% |
| 2020 Q1 | 54 Million SEK | 11.11% |
| 2019 Q4 | 48.6 Million SEK | 86.92% |
| 2019 Q1 | 35 Million SEK | -20.99% |
| 2019 Q3 | 26 Million SEK | -16.13% |
| 2019 Q2 | 31 Million SEK | -11.43% |
| 2019 FY | 140.6 Million SEK | 8.74% |
| 2018 Q2 | 35 Million SEK | 34.62% |
| 2018 FY | 129.3 Million SEK | 7.48% |
| 2018 Q4 | 44.3 Million SEK | 84.58% |
| 2018 Q3 | 24 Million SEK | -31.43% |
| 2018 Q1 | 26 Million SEK | -35.48% |
| 2017 Q2 | 29 Million SEK | 0.0% |
| 2017 FY | 120.3 Million SEK | 7.6% |
| 2017 Q3 | 22 Million SEK | -24.14% |
| 2017 Q1 | 29 Million SEK | -40.94% |
| 2017 Q4 | 40.3 Million SEK | 83.18% |
| 2016 Q2 | 26.4 Million SEK | 56.21% |
| 2016 Q3 | 17.5 Million SEK | -33.71% |
| 2016 Q1 | 16.9 Million SEK | -37.87% |
| 2016 Q4 | 49.1 Million SEK | 180.57% |
| 2016 FY | 111.8 Million SEK | 43.7% |
| 2015 FY | 77.8 Million SEK | -23.73% |
| 2015 Q3 | 9.7 Million SEK | -56.31% |
| 2015 Q4 | 27.2 Million SEK | 180.41% |
| 2015 Q1 | 41 Million SEK | 57.69% |
| 2015 Q2 | 22.2 Million SEK | -45.85% |
| 2014 FY | 102 Million SEK | 30.77% |
| 2014 Q4 | 26 Million SEK | 0.0% |
| 2013 FY | 78 Million SEK | 5.69% |
| 2012 FY | 73.8 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Biotage AB (publ) | 246 Million SEK | 22.764% |
| Bonesupport Holding AB (publ) | 245.02 Million SEK | 22.456% |
| Doxa AB (publ) | 291.9 Million SEK | 34.909% |
| Elekta AB (publ) | 1.3 Billion SEK | 85.407% |
| iZafe Group AB (publ) | -32.17 Million SEK | 690.521% |
| Ortivus AB (publ) | -18.24 Million SEK | 1141.381% |
| Ortivus AB (publ) | -18.24 Million SEK | 1141.381% |
| Q-linea AB (publ) | -229.36 Million SEK | 182.837% |
| S2Medical AB (publ) | -22.7 Million SEK | 936.73% |
| Synsam AB (publ) | 311 Million SEK | 38.907% |